(Q34099969)

31 July 2017

1 reference

title

Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

1

Lucienne Chatenoud

0 references

publication date

1 March 2010

1 reference

Nature Reviews Endocrinology

31 July 2017

1 reference

31 July 2017

6

1 reference

31 July 2017

3

1 reference

31 July 2017

149-157

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.275

31 July 2017

0 references

cites work

B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

The effect of infections on susceptibility to autoimmune and allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Islet-Cell Antibodies and Beta-Cell Function in Monozygotic Triplets and Twins Initially Discordant for Type I Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Breeding of a non-obese, diabetic strain of mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Following a diabetogenic T cell from genesis through pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Tolerance to islet autoantigens in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Suppressor T cells--they're back and critical for regulation of autoimmunity!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Regulatory T cells under scrutiny

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

The role of inflammation in insulitis and beta-cell loss in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Induction of diabetes in standard mice by immunization with the p277 peptide of a 60‐kDa heat shock protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Immunization With the Larger Isoform of Mouse Glutamic Acid Decarboxylase (GAD67) Prevents Autoimmune Diabetes in NOD Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Peptide therapy for diabetes in NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Effects of insulin in relatives of patients with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

GAD treatment and insulin secretion in recent-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

CD40/CD154 interactions at the interface of tolerance and immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Regulating the immune response to transplants. a role for CD4+ regulatory cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

In vitro characterization of five humanized OKT3 effector function variant antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

A controlled trial of natalizumab for relapsing multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

CD3-specific antibody-induced active tolerance: from bench to bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

CD3-specific antibodies: a portal to the treatment of autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Transforming growth factor-beta regulation of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Tolerogenic dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Tolerogenic dendritic cells: cytokine modulation comes of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

beta-cell failure in diabetes and preservation by clinical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Natural versus adaptive regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

CD4+ CD25+ suppressor T cells: more questions than answers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.275

Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells

31 March 2020

1 reference

12 December 2020

Autoimmune diabetes mellitus in the BB rat

1 reference

12 December 2020

Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent

1 reference

12 December 2020

The mechanism of immunological paralysis.

1 reference

12 December 2020

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.

1 reference

12 December 2020

Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen

1 reference

12 December 2020

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

1 reference

12 December 2020

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

1 reference

12 December 2020

Insulin-dependent diabetes mellitus as an autoimmune disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.275

1 reference

31 July 2017

1 reference

PubMed ID

20173776